About HistoSonics
HistoSonics is a company based in Ann Arbor (United States) founded in 2009 was acquired by K5 Global in August 2025. HistoSonics has raised $565.73 million across 12 funding rounds from investors including Varian, University of Michigan and Fletcher Spaght. The company has 56 employees as of December 31, 2022. HistoSonics offers products and services including Histotripsy System and Clinical Trials Platform. HistoSonics operates in a competitive market with competitors including Insightec, Profound Medical, Theraclion, Carthera and SONIRE Therapeutics, among others.
- Headquarter Ann Arbor, United States
- Employees 56 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Histosonics, Inc Attn Christine
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of HistoSonics
HistoSonics offers a comprehensive portfolio of products and services, including Histotripsy System and Clinical Trials Platform.
Non-invasive platform for mechanical destruction of liver tumors.
System for testing histotripsy in oncology applications.
People of HistoSonics
Unlock access to complete
Unlock access to complete
Funding Insights of HistoSonics
HistoSonics has successfully raised a total of $565.73M across 12 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HistoSonics
HistoSonics has secured backing from 27 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Varian, University of Michigan and Fletcher Spaght.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on growth-stage companies
|
Locked | Locked | Locked | |
|
Amzak Health is engaged in venture investments in life sciences.
|
Locked | Locked | Locked | |
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked |
Investor details for HistoSonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HistoSonics
Investment portfolio details for HistoSonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HistoSonics
Detailed financials for HistoSonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Histosonics Comparisons
Peer comparison for HistoSonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HistoSonics
HistoSonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insightec, Profound Medical, Theraclion, Carthera and SONIRE Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided.
|
|
| Locked | Locked | Locked |
Image-guided prostate ablation systems for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of non-invasive robotic ultrasound therapy devices
|
|
| Locked | Locked | Locked |
Ultrasound-based medical devices for brain tumor treatment are developed.
|
|
| Locked | Locked | Locked |
High-intensity focused ultrasound systems for targeted cancer treatments are developed.
|
Detailed competitors of HistoSonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Histosonics
Complete news archive for HistoSonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HistoSonics
HistoSonics was founded in 2009 and raised its 1st funding round 5 years after it was founded.
HistoSonics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Mike Blue is the current CEO of HistoSonics.
HistoSonics is a funded company, having raised a total of $565.73M across 12 funding rounds to date.
As of Dec 31, 2022, the latest employee count at HistoSonics is 56.
HistoSonics was founded in 2009 in Ann Arbor, United States, and focuses on medical technology within the ultrasound therapeutics sector. Histotripsy technology, licensed from the University of Michigan, is developed as a non-invasive, image-guided system that uses pulsed sound waves to create cavitation for mechanical tissue destruction at the cellular level. Applications span cardiovascular, oncology, neurology, and urology fields, targeting tumors, plaque, and other tissues.
HistoSonics's top competitors include Insightec, Profound Medical and Theraclion.
HistoSonics offers Histotripsy System and Clinical Trials Platform.
HistoSonics has 27 investors. Key investors include Varian, University of Michigan, Fletcher Spaght, Signature NY, and Early Stage Partners.